cholangio......I understand what you are saying and therefore recommend the option of gaining access to this drug by enrolling in a clinical trial. Chances of off-label use increase if a Phase II data is released, but at present we are far removed from that.
Investigational use is another (remote) possibility. Here is the information:
Regarding insurance coverage: I hope for someone to come forward and share experiences with us.
Personally, I recall the year 2008 and Avastin ( Bevacizumab.) This angiogenesis inhibitor had not been tested on CCA patients and yet some were approved by their insurance companies whereas others were denied by their individual carriers. In the approved cases a physician contacted the pharmaceutical company directly and then followed up with the insurance carrier.